Phase 1 Trial Recruitment
Atara Biotherapeutics recently published an update of the company’s quarterly financial results and operational highlights, including the advancement of its T-cell based immunotherapy strategies for multiple sclerosis (MS) and cancer. One of the investigational therapies featured in the report is ATA188, a potential treatment for MS. According to the announcement, the company completed patient recruitment for an ongoing Phase 1 study […]
The post Phase 1 Trial Recruitment Complete for Atara’s ATA188 T-cell Immunotherapy for Progressive MS appeared first on Multiple Sclerosis News Today.